Short Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Rises By 27.7%

Aileron Therapeutics, Inc. (NASDAQ:ALRN) was the recipient of a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 141,200 shares, a growth of 27.7% from the December 15th total of 110,600 shares. Based on an average daily volume of 95,500 shares, the days-to-cover ratio is presently 1.5 days. Currently, 0.7% of the company’s shares are sold short.

Institutional Investors Weigh In On Aileron Therapeutics

Several hedge funds have recently modified their holdings of ALRN. KG&L Capital Management LLC purchased a new position in Aileron Therapeutics during the third quarter worth approximately $46,000. Sigma Planning Corp raised its position in shares of Aileron Therapeutics by 68.3% in the 3rd quarter. Sigma Planning Corp now owns 212,410 shares of the company’s stock worth $752,000 after buying an additional 86,185 shares during the period. Geode Capital Management LLC raised its position in shares of Aileron Therapeutics by 34.8% in the 3rd quarter. Geode Capital Management LLC now owns 229,817 shares of the company’s stock worth $814,000 after buying an additional 59,370 shares during the period. Nantahala Capital Management LLC grew its position in Aileron Therapeutics by 82.1% during the second quarter. Nantahala Capital Management LLC now owns 464,367 shares of the company’s stock valued at $1,286,000 after acquiring an additional 209,367 shares during the period. Finally, University of Texas Texas AM Investment Management Co. purchased a new position in shares of Aileron Therapeutics in the 2nd quarter worth about $4,925,000. 90.89% of the stock is owned by institutional investors and hedge funds.

Aileron Therapeutics Stock Performance

The stock has a 50-day simple moving average of $2.52 and a 200-day simple moving average of $2.80. Aileron Therapeutics has a 52 week low of $1.61 and a 52 week high of $7.42.

About Aileron Therapeutics

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).